<DOC>
	<DOC>NCT02727660</DOC>
	<brief_summary>This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)</brief_title>
	<detailed_description>This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study. Subjects will undergo a 1- to 4-week Screening Period. Subjects who successfully complete the Screening Period will be randomized to one of the following three treatment groups: PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID. Following randomization, subjects will enter the Treatment Period and undergo additional treatment visits over 52 weeks.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1. Give their signed written informed consent to participate 2. At least 40 years of age and no older than 80 years of age 3. COPD patients who are symptomatic 4. Must be receiving one or more inhaled bronchodilators as maintenance therapy 5. Must have a documented history of COPD exacerbations 1. Current diagnosis of asthma 2. COPD due to α1Antitrypsin Deficiency 3. Known active tuberculosis, lung cancer, cystic fibrosis, and significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months. 4. Longtermoxygen therapy (≥ 15 hours a day).</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>